Previous 10 | Next 10 |
A changing of the guard is coming at biotech Galapagos (NASDAQ: GLPG) , with the announcement of a new CEO. Investors were quite happy to hear this, and consequently the stock ended the day more than 22% higher. Belgium-based Galapagos announced Wednesday afternoon that it has t...
Succeeds current Chief Executive Officer and co-founder Onno van de Stolpe, following planned retirement Recognized as inspirational industry leader with exceptional R&D as well as global executive experience, and a strong focus on bringing innovative medicines t...
Mechelen, Belgium ; 18 January 202 2 ; 22 .01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Jyseleca ...
Mechelen, Belgium; 13 January 202 2 , 22 . 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its supervisory board created 30,000 subscription rights under a new employee subsc...
Mechelen, Belgium; 6 January 2022, 15.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 40 th A nnual J.P. Morgan Healthcare Conference on January 10-13 , 20 22. Onno van de Stolpe, CE...
Galapagos NV (NASDAQ:GLPG) ADRs are trading ~2.1% higher in the post-market after the company announced a share capital increase, following the subscription right exercises. Galapagos (GLPG) says it issued 22.6K of new ordinary shares on Dec. 03, leading to a €578.7K total ca...
Galapagos is in the midst of a transformation process that is expected to result in a completely different company by 2023. Galapagos has over $5.5 billion in cash, an approved drug and a broad pipeline with a market capitalization of only $3.2 billion. Jyseleca is approved in Jap...
Mechelen, Belgium; 22 November 2021 , 22. 01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant ...
The European Commission has approved Galapagos' (GLPG +0.8%) oral JAK1 inhibitor Jyseleca (filgotinib) for ulcerative colitis. The approval was based on data from the Phase 2b/3 SELECTION program which evaluated filgotinib as an induction and maintenance therapy. The drug was already app...
Mechelen, Belgium; 15 November 2021; 1 6 . 45 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Commission has granted marketing authorization for Jyseleca ® (filgotinib 200mg tablets) for the treatme...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...